Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIP4K2A | P48426 | 1/20 | 0.39 |
| ▸ | PIP4K2B | P78356 | 1/20 | 0.39 |
| ▸ | PLK1 | P53350 | 5/20 | 0.33 |
| ▸ | PLK2 | Q9NYY3 | 5/20 | 0.33 |
| ▸ | STK4 | Q13043 | 3/20 | 0.33 |
| ▸ | PLK3 | Q9H4B4 | 3/20 | 0.32 |
| ▸ | RPS6KA3 | P51812 | 2/20 | 0.32 |
| ▸ | YTHDC1 | Q96MU7 | 1/20 | 0.32 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.31 |
| ▸ | NPBWR1 | P48145 | 1/20 | 0.31 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.31 |
| ▸ | MTOR | P42345 | 1/20 | 0.31 |
| ▸ | TRPC5 | Q9UL62 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4076168 | 0.82 | RPS6KA3 (0.42) | PIP4K2APIP4K2BPLK1PLK2STK4 | |
| SCHEMBL4089766 | 0.81 | VRK1 (0.39) | PIP4K2APIP4K2BSTK4RPS6KA3 | |
| SCHEMBL1203549 | 0.81 | PIP4K2A (0.38) | PIP4K2APIP4K2BPLK1PLK2PLK3 | |
| SCHEMBL4089875 | 0.81 | VRK1 (0.41) | PLK1 | |
| SCHEMBL3668145 | 0.80 | PIP4K2A (0.38) | PIP4K2APIP4K2BPLK1PLK2PLK3 | |
| SCHEMBL3547058 | 0.79 | PLK1 (0.35) | PIP4K2APIP4K2BPLK1PLK3TRPC5 | |
| SCHEMBL4082908 | 0.79 | PIP4K2A (0.36) | PIP4K2APIP4K2BPLK1PLK2STK4 | |
| SCHEMBL3670197 | 0.77 | PIK3CA (0.35) | YTHDC1NPBWR1PIK3CAMTORTRPC5 | |
| SCHEMBL3543190 | 0.76 | TRPC5 (0.36) | PLK1PLK3TRPC5 | |
| SCHEMBL23849175 | 0.74 | PIP4K2A (0.66) | PIP4K2APIP4K2BPLK1PLK2PLK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7517873-B2 | Substituted pyrimidodiazepines | HOFFMAN-LA ROCHE INC. (US) | 2009-04-14 | — | — | US | disclosed |
| US-20080234255-A1 | SUBSTITUTED PYRIMIDODIAZEPINES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-09-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080234255-A1 | SUBSTITUTED PYRIMIDODIAZEPINES | PLK1, CCNI, CDK1 | PIP4K2A 208/4885PIP4K2B 166/4885PLK1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.